September 27, 2019
Otsuka Pharmaceutical said on September 26 that it has filed an application in Japan for the once-monthly injectable version of its antipsychotic Abilify (aripiprazole), seeking an additional indication of the suppression of the recurrence and relapse of mood episodes in...read more